Evidence map›Paper›PMID 35460053›Full record

ArticleMolecular neurobiology2022

Binding Stability of Antibody-α-Synuclein Complexes Predicts the Protective Efficacy of Anti-α-synuclein Antibodies.

Matthias Höllerhage, Andreas Wolff, Tasnim Chakroun, Valentin Evsyukov, Linghan Duan, Oscar Wing-Ho Chua, Qilin Tang, Thomas Koeglsperger, Günter U Höglinger

Open access · hybridAbstract read
In one paragraph

Article in Molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Parkinson's disease therapy: what lies ahead?Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Review
  3. Alpha Synuclein: Neurodegeneration and Inflammation.International journal of molecular sciences · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Matthias HöllerhageDepartment of Neurology, Hannover Medical School, Hannover, D-30625, Germany. hoellerhage.matthias@mh-hannover.de.ORCID http://orcid.org/0000-0002-5333-0121
Andreas WolffDepartment of Neurology, Technical University of Munich (TUM), D-81675, Munich, Germany.
Tasnim ChakrounDepartment of Neurology, Technical University of Munich (TUM), D-81675, Munich, Germany.
Valentin EvsyukovDepartment of Neurology, Hannover Medical School, Hannover, D-30625, Germany.
Linghan DuanDepartment of Neurology, Hannover Medical School, Hannover, D-30625, Germany.
Oscar Wing-Ho ChuaDepartment of Neurology, Hannover Medical School, Hannover, D-30625, Germany.
Qilin TangDepartment of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), D-81377, Munich, Germany.
Thomas KoeglspergerDepartment of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), D-81377, Munich, Germany.
Günter U HöglingerDepartment of Neurology, Hannover Medical School, Hannover, D-30625, Germany.
German Center for Neurodegenerative Diseases · DEMedizinische Hochschule Hannover · DETechnical University of Munich · DE

Funding

BMBF 01EK1605ABMBF 01KU1403ADeutsche Forschungsgemeinschaft HO2402/18-1Deutsche Forschungsgemeinschaft HO2402/6-2Munich Center for Neurosciences - Brain and Mind, Ludwig-Maximilians-Universität München 390857198Niedersächsische Ministerium für Wissenschaft und Kultur ZN3440.TP
6 · The paper itself

Abstract

Spreading of alpha-synuclein (αSyn) may play an important role in Parkinson's disease and related synucleinopathies. Passive immunization with anti-αSyn antibodies is a promising method to slow down the spreading process and thereby the progression of synucleinopathies. Currently, it remains elusive which specific characteristics are essential to render therapeutic antibodies efficacious. Here, we established a neuronal co-culture model, in which αSyn species are being released from αSyn-overexpressing cells and induce toxicity in a priori healthy GFP-expressing cells. In this model, we investigated the protective efficacy of three anti-αSyn antibodies. Only two of these antibodies, one C-terminal and one N-terminal, protected from αSyn-induced toxicity by inhibiting the uptake of spreading-competent αSyn from the cell culture medium. Neither the binding epitope nor the affinity of the antibodies towards recombinant αSyn could explain differences in biological efficacy. However, both protective antibodies formed more stable antibody-αSyn complexes than the non-protective antibody. These findings indicate that the stability of antibody-αSyn complexes may be more important to confer protection than the binding epitope or affinity to recombinant αSyn.

Indexed as

alpha-SynucleinAntibodiesParkinson DiseaseSynucleinopathiesEpitopesHumansNeuronsalpha-SynucleinAntibodiesEpitopesAlpha-synucleinAntibody therapyDisease modelsParkinson’s disease

Identifiers

PMID35460053
PMCPMC9167191
OpenAlexW4224219370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.